Showing results (471-480 of 608) with videos related to

Sort By:
Pageof 61
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 12, 2022
Fingolimod versus interferon beta 1-a: Benefit-harm assessment approach based on TRANSFORMS individual patient dataAlessandra Spanu, Hélène E Aschmann, Jürg Kesselring, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 24, 2021
The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomideStanley Cohan, Tiffany Gervasi-Follmar, Aneesh Kamath, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 13, 2022
Usefulness of two-dimensional measurements for the evaluation of brain volume and disability in multiple sclerosisSatori Ajitomi, Juichi Fujimori, Ichiro Nakashima
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 13, 2022
Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha InhibitorShin Yee Chey, Allan G Kermode
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 18, 2018
Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UKGordon Mazibrada, Charlotte Sharples, Ines Perfect
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 28, 2022
The socioeconomic impact of multiple sclerosis in France: Results from the PETALS studyA Bouleau, C Dulong, C A Schwerer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 2, 2022
Comparison of employment among people with Multiple Sclerosis across EuropeDavid Ellenberger, Tina Parciak, Waldemar Brola, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 2, 2022
Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in SwedenKorinna Karampampa, Hanna Gyllensten, Chantelle Murley, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 10, 2019
Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in SwedenHanna Gyllensten, Andrius Kavaliunas, Chantelle Murley, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 11, 2019
Cannabis-based product use in a multiple sclerosis cohortA J Schabas, V Vukojevic, C Taylor, et al.
Pageof 61